Condition: Unresectable Stage III Non-small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) · Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
This study is a single-arm, phase II clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a neoadjuvant treatment of non-small cell lung cancer.
This description comes directly from the study's public registry record.
Chang Chen, MD · +86 21 65115006 · changchenc@hotmail.com
Always discuss trial participation with your own doctor first.
| Shanghai Pulmonary Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07408635